GSK-3β inhibitor 9 (Compound 9b) is a highly selective, orally bioavailable and potent GSK-3β inhibitor with the IC 50 of 35 nM. GSK-3β inhibitor 9 exhibits good pharmacokinetic profiles including favorable BBB penetration. GSK-3β inhibitor 9 is able to be used for the research of Alzheimer’s disease [1].

GSK-3β inhibitor 9 (Compound 9b) (1-3 mg/kg;1-24 hours; GS rats andC57BL/6N mice) shows good pharmacokinetic profiles and favor able BBB permeability with AUC 0-24h value is 734 ng h/g and K p value (ratio of brain and plasma) is 1.6 [1]. Animal Model: IGS rats (male, 8 weeks old) [1] Dosage: 1 and 3mg/kg Administration: Intravenous injection and oral administration;for 1, 2, 4, 8, 24 hours. Result: 1.19 comp (S)-9b (S)-9c V DSS,iv (mL/kg) 1134 1650 CL total,iv (mL/min/kg) 27.4 28.4 C max,po (ng/mL) 396.9 289.6 AUC 0-24 h,po (ng·h/mL) 1380.6 1229.1 MRT po (h) 2.19 3.03 F d (%) 72.8 65.5